[Expert consensus on the diagnosis and treatment of metastatic paraganglioma and pheochromocytoma].

Approximately 15%-25% paragangliomas and pheochromocytomas (PPGL) can metastasize. Untreated metastatic PPGL (MPP) patients have a 5-year survival rate below 50%, while standardized diagnosis and treatment can significantly improve prognosis. Currently, there has been no established national guidelines for MPP management in China. To address this gap, the Adrenal Group of Chinese Society of Endocrinology convened a multidisciplinary panel of experts from endocrinology, oncology, surgery, nuclear medicine, radiation oncology, pathology, laboratory medicine, and interventional therapy. Based on evidence-based medicine, the latest global research, and clinical data from China, the panel has developed a consensus statement. This consensus encompasses various aspects of MPP, including its epidemiology, pathogenesis, risk factors and prediction for dissemination, clinical manifestations, diagnosis, treatment, and prognosis. A total of 16 recommendation statements have been formulated, with the aim of assisting clinicians in developing standardized strategies for the diagnosis and treatment of MPP.